Creative Biolabs is a leading service provider that focuses on antibody engineering for research, diagnostic and therapeutic use. Our service portfolio includes antibody affinity maturation, antibody stability improvement, chimeric antigen receptor (CAR) construction, scFv/Fab construction and other antibody specialization and modification services.

1. Development of
antibody
engineering

2. CONTENTS
1st generation-- immune serum
2nd generation--hybridoma technology
3rd generation--McAb’s humanization and
miniaturization

3. Backgrouds
The advancement of therapeutic antibodies has included numerous
engineering endeavors in the expectation of enhancing the adequacy,
security, and duration of impacts of counter antibody-based drugs.
Advances in antibody engineering innovations afforded researchers
the ability to get over issues related to bringing foreign antibodies into
a human.
The two heavy chains and two light chains of the antibody are divided
into V and C regions according to the changing degree of amino acid
sequence. Antigen binding specificity is mainly determined by the
hypervariable region in the V region, and the three hypervariable
regions coalesce into a surface which is complementary to the
antigenic determinant. Therefore, it is also known as the
complementarity determining area (CDR). People have tried to use
Antigen binding specificity to assist the diagnosis and treatment of
specific diseases, and then different stages of antibody engineering
technology are gradually formed.

4. PART ONE
1st generation-- immune serum

5. Immune
Serum
There is no doubt that immune serum is the first
generation of antibody engineering decampment. Most
antigenic molecules have multiple epitopes and each
epitope can stimulate a B cell to produce a specific
antibody. Therefore, the traditional immune serum,
also known as polyclonal antibodies has a poor
specificity, prone to cross-reaction, limiting the
application in immunochemical test and disease
diagnosis and treatment.

6. PART TWO
2nd generation--hybridoma technology

7. Hybridoma
Technology Monoclonal antibody (McAb). McAb has a high specificity, strong affinity,
high titer, less serum cross-reaction and other advantages, meeting
application needs of basic research, clinical diagnosis and treatment,
immunization prevention and other areas. Connected with chemicals, toxins
or isotopes, Mcab can effectively deliver therapeutic drugs to Target cell in
virtue of its recognition specificity. This targeting drug therapy, called
"magic bullet" or "biological missile" brought hope for cancer treatment.
However, McAb, as a heterologous protein, can induce anti-mouse antibody
production in vivo, shorten its half-life and reduce the efficacy. Moreover,
the more applications, the less efficacy. high-dose murine heterologous
protein can cause Hypersensitivity and human hybridoma cell lines are
difficult to establish and are prone to chromosome loss. At the same time,
McAb is expensive due to a high production cost and difficult to popularize
the application. And it’s difficult for B cells and myeloma cells to obtain
rare antibodies with their low fusion rate. Although McAb has been widely
used in many fields, it still lags behind in vivo treatment.

8. PART THREE
3rd generation
McAb’s humanization and
miniaturization

9. McAb Starting from the mid-1980s, the third generation of antibodies is expressed by
appropriately transfected receptor cell in the use of recombinant DNA and
protein engineering technology to reform and reassemble. The main function of
the third generation antibody includes McAb’s humanization and
"miniaturization" by recombinant DNA technique and screening and cloning of
new McAb by phage display technology.
Phage antibody library screening usually needs polymerase chain reaction (PCR)
to amplify the full V region gene of antibody and recombine phage vector,
making Fab or ScFv express on the phage surface to form phage antibody
library by forming a fusion protein with Single strand phage coat protein. The
Phage antibody library technology simulates three important steps of antibody
production in vivo: diversity of B cell populations, clonal selection and affinity
mature. This technique eliminates the cell fusion in the traditional McAb
preparation, and can even filter the specific antibody from the library without
immunization, solving the problem of inefficiency of human hybridoma system.

10. With a large screening capacity and
excellent screening ability, easy to produce,
this technology can be directly cloned to
the antibody gene and can be expressed in
the prokaryotic system. All of these
indicate extremely optimistic prospects of
antibody engineering.

11. THANK YOU